SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

What are Mirrored Assets? MIR is the governance token of Mirror Protocol, a synthetic assets protocol built by Terraform Labs (TFL) on the Terra blockchain.  Mirror Protocol is decentralized from day 1, with the on-chain treasury and code changes governed by holders of the MIR token. TFL has no intention of keeping or selling MIR tokens, and there are no admin keys or special access privileges granted. The intent for this is to be a completely decentralized, community-driven project.  Mirrored assets are blockchain tokens that behave like ""mirror"" versions of real-world assets by reflecting the exchange prices on-chain. They give traders the price exposure to real assets while enabling fractional ownership, open access and censorship resistance as any other cryptocurrency. Unlike traditional tokens which serve to represent a real, underlying asset, mAssets are purely synthetic and only capture the price movement of the corresponding asset.

Mirror Protocol

Mirror Protocol (MIR) crypto is experiencing a massive, speculative pump with reports of hundreds of percent gains, driving heated community discussion between aggressive buyers anticipating further rallies and warnings of a 'scam coin' or 'pump and dump' amidst its Terra ecosystem links and recent exchange delistings.

AXT, Inc. engages in the design, development, manufacture and distribution of compound and single element semiconductor substrates. It also sells specialty material substrates and raw materials used to make substrates and other related products. The company was founded by Morris S. Young and Davis Zhang in 1986 and is headquartered in Fremont, CA.

AXT Inc

AXTI is surging as its Q4 earnings report highlighted a narrowing loss and projected sequential revenue growth, driven by escalating demand for its critical indium phosphide substrates in AI infrastructure. The community is buzzing about AXTI's pivotal role in the AI optical supply chain, its planned capacity expansion to address global shortages, and notable institutional buying, despite historical export permit challenges.

Velo3D, Inc. operates as a technology company, which engages in developing and manufacturing metal laser sintering printing machines for 3D printing. Its products include assure system, flow software, sapphire printer & sapphire XC. The company was founded by Benyamin Buller in June 2014 and is headquartered in Fremont, CA.

Velo3D Inc

Velo3D is trending with heightened volatility, driven by recent defense contract wins, U.S. Army qualification, and a new CEO compensation plan tied to aggressive valuation milestones. Community discussion remains sharply divided, balancing optimism for its critical role in aerospace and defense against concerns over institutional exits, high short interest, and potential dilution in its low-float environment.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEAR Protocol is trending due to its strong focus on AI integration and cross-chain capabilities through NEAR Intents, sparking significant community discussion. Recent catalysts like a Grayscale Trust filing and reduced token inflation are fueling investor accumulation amidst anticipation of an altcoin season.

Berachain

Berachain is trending amid sharp community divisions, with bullish sentiment fueled by its Proof-of-Liquidity model and recent network upgrades, while others express concerns over past price volatility and the impact of substantial token unlocks.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending after its latest earnings report revealed lower-than-expected 2026 guidance, sparking community debate over the impact of growing competition from prediction markets on its profitability and future growth. While some investors are expressing concern over high operating costs and market share, others are interpreting the guidance as conservative and view the company's strategic pivot into prediction markets, alongside a recent insider stock purchase, as a potential long-term opportunity amidst an oversold dip.

Carnival Corp. engages in the operation of cruise ships. It operates through the following business segments: North America Cruise Operations, Europe Cruise Operations, Cruise Support, and Tour and Others. The North America Cruise Operations segment includes the Carnival Cruise Line, Holland America Line, Princess Cruises, and Seabourn. Europe Cruise Operations segment consists of AIDA, Costa, Cunard, and P&O Cruises (UK). The Cruise Support segment represents port destinations and private islands for the benefit of its cruise brands. The Tour and Other segment operates hotel and transportation operations of Holland America Princess Alaska Tours. The company was founded in 1972 and is headquartered in Miami, FL.

Carnival Corp. - Ordinary Shares (Paired Stock)

Carnival Corp

Its recent unification under a single company structure and redomiciliation, alongside a reinstated dividend and robust financial recovery, are key drivers for Carnival. The community is highlighting record bookings, strong profitability, and effective debt management, viewing the stock as undervalued despite broader market uncertainties.

Zcash is a privacy-focused cryptocurrency that uses trustless zero-knowledge proofs to enable fully encrypted transactions while maintaining blockchain transparency and security. It was the first cryptocurrency to implement zero-knowledge encryption for private peer-to-peer payments, addressing the fundamental privacy gap in traditional cryptocurrencies that expose transaction details publicly.   With a fixed supply of 21 million ZEC and a halving schedule similar to Bitcoin, Zcash allows users to prove transactions are valid without revealing sensitive information like wallet balances, transaction amounts, or participant identities, making it suitable for everyday payments, long-term savings, and cross-border money transfers where financial confidentiality matters.  The protocol operates on its own blockchain currently using Proof-of-Work consensus, though it's evolving toward Proof-of-Stake through the planned "Crosslink" upgrade to enhance security, scalability, and energy efficiency. Zcash employs trustless zero-knowledge proofs (Halo) within its Orchard shielded pool to verify transactions without revealing sender, receiver, or amount information.   Users can choose between transparent public transactions and shielded private transactions through Unified Addresses, which work with both types. The network is faster and cheaper than Bitcoin, with new blocks mined every 75 seconds and transaction fees typically just a fraction of a cent. Privacy adoption has surged in 2025, with over 30% of total ZEC supply now held in fully shielded pools.  Zcash was created by a group of scientists in 2013 who initially proposed Zerocoin as a privacy extension to Bitcoin before building a standalone protocol. The ecosystem operates with a self-funded development model where block rewards support independent teams through the Zcash Community Grants Committee and a new Coinholder-Controlled Fund.

Zcash

Zcash (ZEC) is trending amid conflicting narratives after the Zcash Foundation announced the SEC concluded its investigation with no enforcement action, sparking optimism for the privacy coin sector. While many anticipate a significant rally, others express skepticism due to recent dev team changes and broader market volatility, leading to a split in community sentiment.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AI is trending due to recent bullish analyst upgrades and strong preliminary financial results signaling robust AI-driven growth and expanding contract agreements in precision oncology. Community discussion centers on its current valuation, significant short interest, and notable institutional purchases from figures like Nancy Pelosi, all in anticipation of its upcoming earnings.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

Johnson & Johnson is currently a focal point as reports surface about a potential $20 billion+ sale of its orthopedics unit to streamline operations, coinciding with strong Q4 earnings and several new drug approvals that bolster its pharmaceutical pipeline. The community, however, remains actively engaged in discussions regarding the significant financial implications of its ongoing talc litigation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Esther Rajavelu Sells 87,917 Shares of Spero Therapeutics (NASDAQ:SPRO) Stock

Spero Therapeutics, Inc. (NASDAQ:SPRO - Get Free Report) insider Esther Rajavelu sold 87,917 shares of the firm's stock in a transaction dated Friday, February 6th. The shares were sold at an average...

Insider Selling: Spero Therapeutics (NASDAQ:SPRO) Insider Sells 18,442 Shares of Stock

Spero Therapeutics, Inc. (NASDAQ:SPRO - Get Free Report) insider Esther Rajavelu sold 18,442 shares of the company's stock in a transaction on Monday, February 2nd. The shares were sold at an average...

Spero Therapeutics (NASDAQ:SPRO) Insider Sells 18,442 Shares

Spero Therapeutics, Inc. (NASDAQ:SPRO - Get Free Report) insider Esther Rajavelu sold 18,442 shares of the business's stock in a transaction dated Monday, February 2nd. The stock was sold at an...

Spero Therapeutics (NASDAQ:SPRO) Stock Price Crosses Below 200 Day Moving Average - What's Next?

Spero Therapeutics (NASDAQ:SPRO) Stock Passes Below 200-Day Moving Average - Time to Sell...

GSK's Q4 Earnings & Sales Beat Estimates, Stock Up on '26 Outlook

GSK's Q4 earnings and sales top estimates as strong specialty medicine demand fuels growth and drives shares higher on an upbeat 2026 outlook.

Spero Therapeutics (NASDAQ:SPRO) Raised to "Buy" at Wall Street Zen

Wall Street Zen upgraded shares of Spero Therapeutics from a "hold" rating to a "buy" rating in a report on Sunday...

Spero Therapeutics (NASDAQ:SPRO) Downgraded by Wall Street Zen to Hold

Wall Street Zen downgraded shares of Spero Therapeutics from a "buy" rating to a "hold" rating in a report on Saturday...

Spero Therapeutics (NASDAQ:SPRO) Stock Crosses Below 200-Day Moving Average - Here's What Happened

Spero Therapeutics (NASDAQ:SPRO) Stock Price Crosses Below 200 Day Moving Average - Here's What Happened...

Spero Therapeutics, Inc. (NASDAQ:SPRO) Sees Large Growth in Short Interest

Spero Therapeutics, Inc. (NASDAQ:SPRO - Get Free Report) saw a significant growth in short interest during the month of December. As of December 15th, there was short interest totaling 1,056,013...

Spero Therapeutics (NASDAQ:SPRO) Stock Price Crosses Below 200 Day Moving Average - Time to Sell?

Spero Therapeutics (NASDAQ:SPRO) Shares Cross Below 200 Day Moving Average - Time to Sell...

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.

Current Price	$2.30
Prev Close	$2.40
Open	$2.38
Dividend Yield	0.00%
50-Day Moving Average	$2.36
Beta	0.86
Avg. Volume	236,507.90
PE Ratio	-2.89

52-Week High	$3.22
52-Week Low	$0.5052
Market Capitalization	$129.58M
EPS (Annual)	-$1.27
Price to Book	4.89
Revenue Per Employee	$856,125.00

SPRO
Spero Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SPRO News

SPROSpero Therapeutics Inc